Susie Brousse
Susie Brousse has a total of 96 co-authors. Here are the top co-authors by number of shared publications:
- Carole Mathelin
Institut de Cancérologie Strasbourg Europe (ICANS), Strasbourg, France
6 shared publications - Vincent Lavoué
Department of Gynaecology, CHU de Rennes, France; INSERM, 1242, COSS, Rennes, Université de Rennes 1, France
5 shared publications - Charlotte Vaysse
Département de chirurgie oncologique, CHU de Toulouse, institut universitaire du cancer de Toulouse-Oncopole, Toulouse, France
4 shared publications - Sébastien Molière
Department of Women’s Imaging, University Hospitals of Strasbourg, 67200 Strasbourg, France
4 shared publications - Catherine Uzan
Hôpital Pitié-Salpêtrière, 47, boulevard de l'Hôpital, 75013 Paris, France
3 shared publications E. Beraud
Service de radiologie, hôpital Sud, 16, boulevard de Bulgarie, 35200 Rennes, France
2 shared publications
Latest Publications
- 2 October 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Identification of cellular determinants of responseto systemic treatment in triple-negative breast carcinomas
Identification des déterminants cellulaires de la réponse au traitement systémique dans les carcinomes mammaires triple-négatifs: Introduction – Le cancer du sein triple-négatif (CSTN) est un sous-type moléculaire moins fréquent mais plus agressif de cancer du sein que l’on retrouve notamment chez des patientes plus jeunes. S’il ne possède pas de cible thérapeutique spécifique, la découverte de sa forte immunogénicité a permis le développement de nouvelles thérapeutiques sous forme d’immunothérapie, y compris en situation néoadjuvante. Néanmoins, pour mieux comprendre et prédire la réponse aux traitements, une meilleure caractérisation immune est nécessaire. Méthodes – Après une caractérisation de 91 CSTN par cytométrie en flux (CMF), 19 de ces tumeurs ont été caractérisées par IHC multiplexe par technique Hyperion et 25 par analyse transcriptomique. En parallèle, un modèle murin a été développé tout comme une étude radiomique prospective. Résultats – Après caractérisation des sous-populations immunes par CMF, seuls les lymphocytes CD4+ (LT CD4+) Th2 avaient une valeur pronostique pour la survie sans récidive et globale, notamment plus forte que les TILs. Les tentatives de validations orthogonales ont permis de retrouver des valeurs de leucocytes CD45+, LT CD4+, voire CD 8+, corrélées en IHC et transcriptomique mais ont manqué de puissance pour que cela puisse être le cas pour les Th2. Par ailleurs, pour une meilleure corrélation aux schémas néoadjuvants actuels, un modèle murin a été créé permettant l’étude des sous-populations immunes et une analyse radiomique a été menée sur une cohorte prospective. Conclusion – Les LT CD4+ Th2 mesurés par CMF ont une valeur pronostique en adjuvant mais celle-ci, tout comme celle prédictive, restent à prouver en néoadjuvant par différentes techniques utilisables en pratique clinique.
- 2 October 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Identification of cellular determinants of responseto systemic treatment in triple-negative breast carcinomas
Identification des déterminants cellulaires de la réponse au traitement systémique dans les carcinomes mammaires triple-négatifs: Introduction – Le cancer du sein triple-négatif (CSTN) est un sous-type moléculaire moins fréquent mais plus agressif de cancer du sein que l’on retrouve notamment chez des patientes plus jeunes. S’il ne possède pas de cible thérapeutique spécifique, la découverte de sa forte immunogénicité a permis le développement de nouvelles thérapeutiques sous forme d’immunothérapie, y compris en situation néoadjuvante. Néanmoins, pour mieux comprendre et prédire la réponse aux traitements, une meilleure caractérisation immune est nécessaire. Méthodes – Après une caractérisation de 91 CSTN par cytométrie en flux (CMF), 19 de ces tumeurs ont été caractérisées par IHC multiplexe par technique Hyperion et 25 par analyse transcriptomique. En parallèle, un modèle murin a été développé tout comme une étude radiomique prospective. Résultats – Après caractérisation des sous-populations immunes par CMF, seuls les lymphocytes CD4+ (LT CD4+) Th2 avaient une valeur pronostique pour la survie sans récidive et globale, notamment plus forte que les TILs. Les tentatives de validations orthogonales ont permis de retrouver des valeurs de leucocytes CD45+, LT CD4+, voire CD 8+, corrélées en IHC et transcriptomique mais ont manqué de puissance pour que cela puisse être le cas pour les Th2. Par ailleurs, pour une meilleure corrélation aux schémas néoadjuvants actuels, un modèle murin a été créé permettant l’étude des sous-populations immunes et une analyse radiomique a été menée sur une cohorte prospective. Conclusion – Les LT CD4+ Th2 mesurés par CMF ont une valeur pronostique en adjuvant mais celle-ci, tout comme celle prédictive, restent à prouver en néoadjuvant par différentes techniques utilisables en pratique clinique.
- Open Access
- 25 June 2025
- Published by Elsevier in Innovative Practice in Breast Health
- Vol. 7
Proposed French recommendations for breast cancer screening in the trans population
- 25 June 2025
- Published by Elsevier in Innovative Practice in Breast Health
- Vol. 7
Open AccessProposed French recommendations for breast cancer screening in the trans population
- Open Access
- 29 May 2025
- Published by Galenos Yayinevi in European Journal of Breast Health
- Vol. 21 (3) , 200-210
What Changes are Mandatory in Breast Surgery Training? An International Survey and Recommendations of the French Academy of Surgery and the Senologic International Society
What Changes are Mandatory in Breast Surgery Training? An International Survey and Recommendations of the French Academy of Surgery and the Senologic International Society - European Journal of Breast Health
- 29 May 2025
- Published by Galenos Yayinevi in European Journal of Breast Health
- Vol. 21 (3) , 200-210
Open AccessWhat Changes are Mandatory in Breast Surgery Training? An International Survey and Recommendations of the French Academy of Surgery and the Senologic International Society
What Changes are Mandatory in Breast Surgery Training? An International Survey and Recommendations of the French Academy of Surgery and the Senologic International Society - European Journal of Breast Health
- 18 January 2024
- Published by Elsevier in Gynécologie Obstétrique Fertilité & Sénologie
- Vol. 52 (3) , 158-164
Comment l’activité physique pourrait-elle réduire le risque de survenue et de récidive des cancers du sein ?
- 18 January 2024
- Published by Elsevier in Gynécologie Obstétrique Fertilité & Sénologie
- Vol. 52 (3) , 158-164
Comment l’activité physique pourrait-elle réduire le risque de survenue et de récidive des cancers du sein ?
- 6 January 2024
- Published by Elsevier in Gynécologie Obstétrique Fertilité & Sénologie
- Vol. 52 (3) , 132-141
Peut-on surseoir au curage axillaire en cas de carcinome mammaire invasif avec envahissement ganglionnaire ?
- 6 January 2024
- Published by Elsevier in Gynécologie Obstétrique Fertilité & Sénologie
- Vol. 52 (3) , 132-141
Peut-on surseoir au curage axillaire en cas de carcinome mammaire invasif avec envahissement ganglionnaire ?
- 18 December 2023
- Published by Elsevier in Gynécologie Obstétrique Fertilité & Sénologie
- Vol. 52 (3) , 125-131
Actualisation des indications chirurgicales et des indicateurs de qualité et sécurité des soins dans la prise en charge des carcinomes mammaires invasifs
- 18 December 2023
- Published by Elsevier in Gynécologie Obstétrique Fertilité & Sénologie
- Vol. 52 (3) , 125-131
Actualisation des indications chirurgicales et des indicateurs de qualité et sécurité des soins dans la prise en charge des carcinomes mammaires invasifs
- Open Access
Th2 infiltration is a better predictor of survival than tumor-infiltrating lymphocytes (TILs) in triple-negative breast cancer (TNBC)
Purpose: Triple-negative breast cancers (TNBC) account for 15% of all breast cancers but carry the worst prognosis. Because of their heterogenicity, these tumors are not all prone to targeted therapies. However, due to their high immune infiltration, targeting their immune microenvironment is of tremendous interest and is becoming the standard of care for high-risk early-stage TNBC. Nevertheless, the characterization of this immune infiltrate is often limited to general tumor-infiltrating lymphocytes (TILs) counting, without characterization of lymphocytes subtypes. Thus, we aimed at precisely characterizing these sub-populations and evaluating their prognostic significance. Methods: We selected 91 TNBC tumors for which we had both the TILs count on hematoxylin and eosin (H&E) slides determined by an expert pathologist and the immune microenvironment cell subtypes characterization using flow cytometry (FC). We then compared the prognostic value of immune microenvironment subpopulations vs total TILs count. Results: TNBCs contained a mean of 22.8±25.9% TILs in the tumor surface area, including mainly CD4+ helper T lymphocytes (14.1%), mostly Th2 (11.7%), CD8+ cytotoxic T lymphocytes (11.1%), and myeloid cells (8.4%) including antigen presenting cells (APC). The TILs count was correlated with the abundance of these cellular subpopulations (p≤0.004). TILs percentage was predictive of overall survival (OS) in univariate analysis (p=0.044), high APC infiltration was predictive of relapse-free survival (RFS) in univariate analysis (p≤0.030), and Th2 infiltration was predictive of both RFS and OS in univariate (p=0.009, 0.008 respectively) and multivariate analyses (p=0.002, 0.010 respectively). Conclusion: The characterization of TILs composition is essential to better understand the potential antitumoral functions of these cells, and to strongly improve the associated prognostic and predictive values. We here demonstrate that Th2 subpopulation is associated with a better overall survival in TNBC and could be of use to predict response to the newly used immunotherapies.
Open AccessTh2 infiltration is a better predictor of survival than tumor-infiltrating lymphocytes (TILs) in triple-negative breast cancer (TNBC)
Purpose: Triple-negative breast cancers (TNBC) account for 15% of all breast cancers but carry the worst prognosis. Because of their heterogenicity, these tumors are not all prone to targeted therapies. However, due to their high immune infiltration, targeting their immune microenvironment is of tremendous interest and is becoming the standard of care for high-risk early-stage TNBC. Nevertheless, the characterization of this immune infiltrate is often limited to general tumor-infiltrating lymphocytes (TILs) counting, without characterization of lymphocytes subtypes. Thus, we aimed at precisely characterizing these sub-populations and evaluating their prognostic significance. Methods: We selected 91 TNBC tumors for which we had both the TILs count on hematoxylin and eosin (H&E) slides determined by an expert pathologist and the immune microenvironment cell subtypes characterization using flow cytometry (FC). We then compared the prognostic value of immune microenvironment subpopulations vs total TILs count. Results: TNBCs contained a mean of 22.8±25.9% TILs in the tumor surface area, including mainly CD4+ helper T lymphocytes (14.1%), mostly Th2 (11.7%), CD8+ cytotoxic T lymphocytes (11.1%), and myeloid cells (8.4%) including antigen presenting cells (APC). The TILs count was correlated with the abundance of these cellular subpopulations (p≤0.004). TILs percentage was predictive of overall survival (OS) in univariate analysis (p=0.044), high APC infiltration was predictive of relapse-free survival (RFS) in univariate analysis (p≤0.030), and Th2 infiltration was predictive of both RFS and OS in univariate (p=0.009, 0.008 respectively) and multivariate analyses (p=0.002, 0.010 respectively). Conclusion: The characterization of TILs composition is essential to better understand the potential antitumoral functions of these cells, and to strongly improve the associated prognostic and predictive values. We here demonstrate that Th2 subpopulation is associated with a better overall survival in TNBC and could be of use to predict response to the newly used immunotherapies.
- 1 February 2022
- Published by Elsevier in Gynécologie Obstétrique Fertilité & Sénologie
- Vol. 50 (2) , 107-120
Indications des mastectomies de réduction de risque en dehors du risque avéré de prédisposition héréditaire : recommandations du Collège national des gynécologues et obstétriciens français (CNGOF)
- 1 February 2022
- Published by Elsevier in Gynécologie Obstétrique Fertilité & Sénologie
- Vol. 50 (2) , 107-120
Indications des mastectomies de réduction de risque en dehors du risque avéré de prédisposition héréditaire : recommandations du Collège national des gynécologues et obstétriciens français (CNGOF)
- Open Access
Early, On-Treatment Levels and Dynamic Changes of Genomic Instability in Circulating Tumor DNA Predict Response to Treatment and Outcome in Metastatic Breast Cancer Patients
Background: Circulating tumor DNA (ctDNA) offers high sensitivity and specificity in metastatic cancer. However, many ctDNA assays rely on specific mutations in recurrent genes or require the sequencing of tumor tissue, difficult to do in a metastatic disease. The purpose of this study was to define the predictive and prognostic values of the whole-genome sequencing (WGS) of ctDNA in metastatic breast cancer (MBC). Methods: Plasma from 25 patients with MBC were taken at the baseline, prior to treatment (T0), one week (T1) and two weeks (T2) after treatment initiation and subjected to low-pass WGS. DNA copy number changes were used to calculate a Genomic Instability Number (GIN). A minimum predefined GIN value of 170 indicated detectable ctDNA. GIN values were correlated with the treatment response at three and six months by Response Evaluation Criteria in Solid Tumours assessed by imaging (RECIST) criteria and with overall survival (OS). Results: GIN values were detectable (>170) in 64% of patients at the baseline and were significantly prognostic (41 vs. 18 months OS for nondetectable vs. detectable GIN). Detectable GIN values at T1 and T2 were significantly associated with poor OS. Declines in GIN at T1 and T2 of > 50% compared to the baseline were associated with three-month response and, in the case of T1, with OS. On the other hand, a rise in GIN at T2 was associated with a poor response at three months. Conclusions: Very early measurements using WGS of cell-free DNA (cfDNA) from the plasma of MBC patients provided a tumor biopsy-free approach to ctDNA measurement that was both predictive of the early tumor response at three months and prognostic.
Open AccessEarly, On-Treatment Levels and Dynamic Changes of Genomic Instability in Circulating Tumor DNA Predict Response to Treatment and Outcome in Metastatic Breast Cancer Patients
Background: Circulating tumor DNA (ctDNA) offers high sensitivity and specificity in metastatic cancer. However, many ctDNA assays rely on specific mutations in recurrent genes or require the sequencing of tumor tissue, difficult to do in a metastatic disease. The purpose of this study was to define the predictive and prognostic values of the whole-genome sequencing (WGS) of ctDNA in metastatic breast cancer (MBC). Methods: Plasma from 25 patients with MBC were taken at the baseline, prior to treatment (T0), one week (T1) and two weeks (T2) after treatment initiation and subjected to low-pass WGS. DNA copy number changes were used to calculate a Genomic Instability Number (GIN). A minimum predefined GIN value of 170 indicated detectable ctDNA. GIN values were correlated with the treatment response at three and six months by Response Evaluation Criteria in Solid Tumours assessed by imaging (RECIST) criteria and with overall survival (OS). Results: GIN values were detectable (>170) in 64% of patients at the baseline and were significantly prognostic (41 vs. 18 months OS for nondetectable vs. detectable GIN). Detectable GIN values at T1 and T2 were significantly associated with poor OS. Declines in GIN at T1 and T2 of > 50% compared to the baseline were associated with three-month response and, in the case of T1, with OS. On the other hand, a rise in GIN at T2 was associated with a poor response at three months. Conclusions: Very early measurements using WGS of cell-free DNA (cfDNA) from the plasma of MBC patients provided a tumor biopsy-free approach to ctDNA measurement that was both predictive of the early tumor response at three months and prognostic.